Topical pan-JAK-i vs. systemic retinoid: head-to-head study

Alitretinoin is currently the only systemic treatment approved for severe chronic hand eczema when patients do not respond adequately to topical corticosteroids. The topical pan-Janus kinase (JAK) inhibitor delgocitinib is now also available as a further escalation option for these cases. In the DELTA-FORCE study, the two treatment options were directly compared, with delgocitinib proving to be superior.